CSL Limited Annual Report 2022/23 11 Immunology Clinical Registration Post-Launch HAEGARDA®/BERINERT® (C1 Esterase Inhibitor SC & IV) Hereditary Angioedema HIZENTRA® (20% subcutaneous Ig) Multiple Indications PRIVIGEN® (10% intravenous Ig) Multiple Indications Garadacimab (Anti-FXIIa mAb) Hereditary Angioedema HIZENTRA® (20% subcutaneous Ig) Dermatomyositis HIZENTRA® (20% subcutaneous Ig) Systemic Sclerosis Anumigilumab (Anti-G-CSFRmAb) Hidradenitis Suppurativa CSL730 (Recombinant Trivalent Human IgG1 Fc Multimer) Multiple Indications*† Haematology Clinical Registration Post-Launch AFSTYLA® (Recombinant FVIII) Haemophilia A IDELVION® (Recombinant FIX-FP) Haemophilia B HEMGENIX® (Recombinant adeno-associated viral vector with codon-optimized Padua derivative of Human FIX cDNA) Haemophilia B* KCENTRA® (Prothrombin Complex Concentrate) Trauma VAMIFEPORT® (Ferroportin inhibitor) Sickle Cell Disease CSL301 (α2 Anti-Plasmin mAb) Sub-acute Pulmonary Embolism* CSL889 (Hemopexin) Sickle Cell Disease Respiratory Clinical Registration Post-Launch ZEMAIRA®/RESPREEZA® (Alpha 1 Antitrypsin) AAT Deficiency Garadacimab (Anti-FXIIa mAb) Interstitial Lung Disease/Idiopathic Pulmonary Fibrosis Trabikibart (Anti-Beta Common mAb) Asthma CSL787 (Nebulised Ig) Non-Cystic Fibrosis Bronchiectasis Cardiovascular and Metabolic Clinical Registration Post-Launch CSL112 Apolipoprotein A-I (human) Acute Myocardial Infarction Clazakizumab (Anti-IL-6 mAb) End Stage Kidney Disease Transplant Clinical Registration Post-Launch Clazakizumab (Anti-IL-6 mAb) Chronic Active Antibody-Mediated Rejection CSL964 (Alpha 1 Antitrypsin) Prevention of Acute Graft-versus-Host Disease CSL964 (Alpha 1 Antitrypsin) Treatment of Acute Graft-versus-Host Disease* Vaccines Clinical Registration Post-Launch AUDENZ™ (Adjuvanted Cell-based Pandemic Vaccine) Influenza A (H5N1) FLUAD® (Adjuvanted Trivalent Vaccine) Influenza FLUAD® (Adjuvanted Quadrivalent Vaccine) Influenza FLUCELVAX® (Quadrivalent Cell-based Vaccine) Influenza FOCLIVIA®/AFLUNOV® (Adjuvanted Egg-based Pandemic Vaccine) Influenza A (H5N1) ARCT-154 (COVID-19 Vaccine)* Adjuvanted Quadrivalent Cell Culture Vaccine Influenza (aQIVc) CSL Vifor Clinical Registration Post-Launch FERINJECT® (Ferric carboxymaltose) Iron Deficiency KORSUVA®/KAPRUVIA® (Kappa Opioid Receptor Agonist) Chronic Kidney Disease-associated Pruritus 1 RAYALDEE® (Oral ext. release Calcifediol) Secondary Hyperparathyroidism 2 TAVNEOS® (Oral C5a Receptor Inhibitor) Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis 3 VELPHORO® (Sucroferric Oxyhydroxide) SerumPhosphorous control in Chronic Kidney Disease VELTASSA® (Oral PotassiumBinder) Hyperkalemia INJECTAFER® (Ferric carboxymaltose) Heart Failure in Iron Deficiency Sparsentan (Dual ETA & AT1 antagonist) IgA Nephropathy 4 Sparsentan (Dual ETA & AT1 antagonist) Focal Segmental Glomerulosclerosis4 SNF472 (Vascular Calcification Inhibitor) Calcific Uraemic Arteriolopathy in End Stage Kidney Disease† SNF472 (Vascular Calcification Inhibitor) Peripheral Artery Disease in End Stage Kidney Disease INS-3001 (Calcification Inhibitor) Peripheral Artery Disease, Aortic Valve Stenosis Outlicensed Programs Clinical Registration Post-Launch Eblasakimab (Anti-IL-13RmAb) Atopic Dermatitis Mavrilimumab (Anti-GM-CSFRmAb) Giant Cell Arteritis, Rheumatoid Arthritis 5 LASN01 (Anti-IL-11 mAb) Idiopathic Pulmonary Fibrosis, Thyroid Eye Disease *Partnered Project. †Project discontinued. 1. KORSUVA®/KAPRUVIA® is a registered trademark of Cara Therapeutics, Inc.; 2. RAYALDEE® is a registered trademark of OPKO Health, Inc.; 3. TAVNEOS® is a registered trademark of ChemoCentryx Inc.; 4. Sparsentan is licensed from Travere Therapeutics, Inc.; 5. Mavrilimumab Phase II studies in GCA & RA complete. Kiniksa evaluating development in rare cardiovascular diseases. CSL’s pipeline also includes Life Cycle Management projects that address regulatory post-marketing commitments, pathogen safety, capacity expansions, yield improvements, and new packages and sizes. Global Research and Development Pipeline 2022/23
RkJQdWJsaXNoZXIy MjE2NDg3